↓ Skip to main content

American Association for Cancer Research

A Novel Sulindac Derivative Inhibits Lung Adenocarcinoma Cell Growth through Suppression of Akt/mTOR Signaling and Induction of Autophagy

Overview of attention for article published in Molecular Cancer Therapeutics, May 2013
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

patent
11 patents

Citations

dimensions_citation
36 Dimensions

Readers on

mendeley
21 Mendeley
Title
A Novel Sulindac Derivative Inhibits Lung Adenocarcinoma Cell Growth through Suppression of Akt/mTOR Signaling and Induction of Autophagy
Published in
Molecular Cancer Therapeutics, May 2013
DOI 10.1158/1535-7163.mct-12-0785
Pubmed ID
Authors

Evrim Gurpinar, William E. Grizzle, John J. Shacka, Burton J. Mader, Nan Li, Nicholas A. Piazza, Suzanne Russo, Adam B. Keeton, Gary A. Piazza

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 21 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 5%
Unknown 20 95%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 24%
Student > Bachelor 3 14%
Professor > Associate Professor 3 14%
Researcher 3 14%
Student > Doctoral Student 2 10%
Other 4 19%
Unknown 1 5%
Readers by discipline Count As %
Medicine and Dentistry 7 33%
Agricultural and Biological Sciences 6 29%
Biochemistry, Genetics and Molecular Biology 3 14%
Pharmacology, Toxicology and Pharmaceutical Science 2 10%
Chemistry 2 10%
Other 0 0%
Unknown 1 5%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 June 2023.
All research outputs
#7,557,593
of 23,053,169 outputs
Outputs from Molecular Cancer Therapeutics
#1,686
of 3,876 outputs
Outputs of similar age
#65,777
of 194,396 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#32
of 52 outputs
Altmetric has tracked 23,053,169 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,876 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one is in the 31st percentile – i.e., 31% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 194,396 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 52 others from the same source and published within six weeks on either side of this one. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.